<SEC-DOCUMENT>0001193125-21-299319.txt : 20211015
<SEC-HEADER>0001193125-21-299319.hdr.sgml : 20211015
<ACCEPTANCE-DATETIME>20211015060658
ACCESSION NUMBER:		0001193125-21-299319
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211015
FILED AS OF DATE:		20211015
DATE AS OF CHANGE:		20211015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		211324731

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d195104d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission
File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jielun Zhu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October&nbsp;15, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1 &#151; Press Release </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d195104dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g195104ex99_1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Advances Late-stage Development of Its Differentiated CD38
Antibody Felzartamab (TJ202) in China </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide
for second-line treatment of multiple myeloma (MM)</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>New IND application for combination of felzartamab with another <FONT STYLE="white-space:nowrap">I-Mab</FONT>
clinical asset as a potential first-line treatment for MM is planned in Q4 2021 </I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI, China and GAITHERSBURG, MD.,</B>
<B>October 13, 2021 </B>&#150; <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today
announced that it has completed the patient enrollment of the phase 3 clinical trial of human CD38 antibody felzartamab (also known as TJ202) in combination with lenalidomide as a second-line therapy in patients with multiple myeloma (MM). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The phase 3 trial (NCT03952091) is a randomized, open-label, parallel-controlled, multi-center study to evaluate the efficacy and safety of the combination of
felzartamab, lenalidomide (LEN) and dexamethasone (DEX) versus the combination of LEN and DEX in patients with relapsed or refractory MM who received at least one prior line of treatment. The primary endpoint of the study is to evaluate the
progression-free survival (PFS) comparing the efficacy of felzartamab plus LEN/DEX versus LEN/DEX. Data from this study are expected to be the major package supporting Biologics License Application (BLA) submission for second-line treatment of MM in
China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to have completed the patient enrollment as planned under very challenging circumstances. The results will further support
the clinical program towards registration to treat patients with multiple myeloma in China,&#148; said Dr.&nbsp;Joan Shen, CEO of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> has completed the <FONT STYLE="white-space:nowrap">single-arm</FONT> registrational trial with felzartamab and
DEX as a third-line therapy for MM patients in Greater China (NCT03860038). Topline data from the study has met the primary and secondary endpoints and confirmed its clinical advantages as estimated. BLA submission is on track in Q4 2021. Further, a
new IND application is planned in Q4 2021 to initiate a clinical trial for combination of felzartamab with another <FONT STYLE="white-space:nowrap">I-Mab</FONT> clinical asset as a potential first-line treatment for MM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>### </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Felzartamab </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Felzartamab (TJ202/MOR202) is an investigational human monoclonal antibody derived from MorphoSys&#146;
HuCAL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody technology. The antibody is directed against CD38 on the surface of multiple myeloma cells, which has been characterized as one of the most strongly and uniformly expressed
antigens on the surface of malignant plasma cells. According to its suggested mode of action, the antibody recruits cells of the body&#146;s immune system to kill the tumor through antibody-dependent cellular cytotoxicity (ADCC) and
antibody-dependent cellular phagocytosis (ADCP). The antibody does not involve complement dependent cytotoxicity, or CDC, an additional immune mechanism involved in tumor cell killing. Scientific research suggests that an anti-CD38 antibody may have
therapeutic potential also in other cancers as well as autoimmune diseases. Based on a licensing agreement between MorphoSys and <FONT STYLE="white-space:nowrap">I-Mab</FONT> signed in November 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
owns the exclusive rights for development and commercialization of TJ202/MOR202 in mainland China, Taiwan, Hong Kong and Macao. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shanghai (HQ)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">88&nbsp;Shangke&nbsp;Road,&nbsp;Pudong&nbsp;New&nbsp;District</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shanghai, China</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite&nbsp;710,&nbsp;9801&nbsp;Washingtonian&nbsp;Blvd</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><U>www.i-mabbiopharma.com</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g195104ex99_1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HuCAL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of MorphoSys AG.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon
commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company&#146;s mission is to bring transformational medicines to patients around the world through drug innovation. <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> globally competitive pipeline of more than 15 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by its internal R&amp;D capability and global licensing
partnerships, based on the Company&#146;s unique <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Proof-of-Concept</FONT></FONT></FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical
company with cutting-edge global R&amp;D capabilities, a world-class GMP manufacturing facility and commercialization capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has established its global footprint in Shanghai (headquarters), Beijing,
Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit&nbsp;<U><FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U>&nbsp;and follow <FONT
STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U> and <U>WeChat</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities
laws, including statements regarding data from the felzartamab clinical trials, the potential implications of clinical data for patients, and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> advancement of, and anticipated clinical development,
regulatory milestones and commercialization of felzartamab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing
of decisions made by the relevant regulatory authorities regarding regulatory approval of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial
success for its drug candidates, if approved; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain and maintain protection of intellectual property for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
reliance on third parties to conduct drug development, manufacturing and other services; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain
additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial
and other operations, as well as those risks more fully discussed in the &#147;Risk Factors&#148; section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well
as discussions of potential risks, uncertainties, and other important factors in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on
information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT></U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Communications Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT></U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc. </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emilie Wu </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>emilie@thepiacentegroup.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shanghai (HQ)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">88&nbsp;Shangke&nbsp;Road,&nbsp;Pudong&nbsp;New&nbsp;District</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shanghai, China</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite&nbsp;710,&nbsp;9801&nbsp;Washingtonian&nbsp;Blvd</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><U>www.i-mabbiopharma.com</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g195104ex99_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g195104ex99_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!X17AI9@  34T *@    @ !@$Q  (
M   1    5@,!  4    !    : ,#  $    !     %$0  $    ! 0   %$1
M  0    !   .Q%$2  0    !   .Q     !-:6-R;W-O9G0@3V9F:6-E
M 8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'
M!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#
M!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,#/_  !$( #@ FP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MSYX-\:W%E%IL_BC2H-1>UC<R+ 9%#;0Q )QGK7Q'^V__ ,%V)_V7_P!I;7_
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M3&<+V!.>3@>'<UQ'P\L3/KIEV_+;QD].YX']:[F&&2XE6-%9F8X '>O\OOI
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>KZ@]4**** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
